The long awaited results of the adjuvant BILCAP study
- This topic has 18 replies, 5 voices, and was last updated 7 years, 1 month ago by
.
-
Posts
-
John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial.
Video discussion.
The other study: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)
https://clinicaltrials.gov/ct2/show/NCT02170090
Results should be released in 2022.Additionally wer are awaiting data from the Chinese study gemcitabine/oxaliplatin (GEMOX) compared with capecitabine. These results are expected to be released in 2018.
Hugs
MarionThe median overall survival was 15 months longer with xeloda than wothout. Not a 15 total month survival. I believe it was actually 50 months with vs 36 months without the xeloda post op. Also interesting that he spoke of another trial in europe that may compare gem/cis vs xeloda for adjuvant therapy.
-billyChief investigator Dr. John Primrose discuss the available data so far retrieved. More data will be analysed.
Highlights: Hilar operations are more invasive than that of intrahepatic CCA.
Some patients were not physicially able to enter this trial post surgery at 12 weeks. Study changed and integrated patients with 16 weeks post resection.
Medium Overall Survival was 15 months. Note: this is the average – some faired better others did not fair as well.
See more here:
http://www.ascopost.com/videos/2017-asco-annual-meeting/john-marshall-md-and-john-neil-primrose-phd-mbbs-on-biliary-tract-cancer-results-from-the-bilcap-trial/?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=6714009“These results are very intriguing. There is no current standard of care for adjuvant therapy of biliary tract cancer” says Dr. Lipika.
http://www.ascopost.com/issues/may-25-2017/expert-point-of-view-lipika-goyal-md/
Julie…we must believe you benefitted as well. That’s the great mystery of cancer treatment some benefit whereas others do not. Let’s see what comes out of the discussion.
Hugs
MarionWhile at ASCO I will have the opportunity to meet up with their team and others to discuss more details. All info will be forthcoming.
Hugs
MarionThanks for posting that news. Good to read that finally something is coming from that. Now, I just would be interested in knowing if Gem /Cis given after a resection has any benefit for people like I was. I really shouldn’t look back…..what’s done is done.
ASCO link here.
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
http://abstracts.asco.org/199/AbstView_199_186869.html
Very big indeed Marion and the more the article is placed the better I would say!!! Hope that everyone reads it.
It’s big news, Gavin. Thought to place the article here as well:
- The forum ‘Clinical Trials’ is closed to new topics and replies.